Day One Biopharmaceuticals, INC. (DAWN) — 10-Q Filings

All 10-Q filings from Day One Biopharmaceuticals, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

DAWN's Q3 Loss Widens Amidst Plummeting License Revenue — Nov 4, 2025 Risk: high
Day One Biopharmaceuticals, Inc. (DAWN) reported a net loss of $19.7 million for the three months ended September 30, 2025, a significant decline from the net i
Day One Biopharma Posts No Revenue, $109.8M Net Loss in Q2 — Aug 5, 2025 Risk: high
Day One Biopharmaceuticals, Inc. reported no product revenue for the three and six months ended June 30, 2025, consistent with the prior year, indicating its pr
Day One Bio Q1 2025 Update: R&D, Revenue Details — May 6, 2025 Risk: medium
Day One Biopharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance, including research and developme
Day One Bio Q3 2024 Filing — Oct 30, 2024 Risk: medium
Day One Biopharmaceuticals, Inc. filed its Q3 2024 10-Q report on October 30, 2024. The company's fiscal year ends on December 31st. Key financial data points a
Day One Bio Files Q2 2024 10-Q — Aug 2, 2024 Risk: medium
Day One Biopharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates. Key finan
Day One Biopharmaceuticals Files 10-Q for Period Ending March 31, 2024 — May 6, 2024 Risk: medium
Day One Biopharmaceuticals, Inc. (DAWN) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Day One Biopharmaceuticals, Inc. filed a 10-Q report for th

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX